A Phase II/III Adaptive Crossover Study of Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke
Latest Information Update: 10 Jan 2018
At a glance
- Drugs NSI 566 (Primary)
- Indications Paralysis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neuralstem China
- 10 Jan 2018 New trial record